Should I Buy BTMD? BTMD 2026 Analysis

Should You Buy Biote Corp (BTMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.200

1 Day change

-1.35%

52 Week Range

5.000

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: the trend is still bearish (SMA_200 > SMA_20 > SMA_5) and the pattern-based next-day bias is negative.
The stock is near the pivot (~2.19) with overhead resistance at ~2.32; upside looks capped in the very near term unless it breaks and holds above resistance.
Longer-horizon upside is plausible (insider buying surge + analyst still at Buy + 1-month pattern upside), but without a proprietary buy signal today, the risk/reward for an immediate chase is not favorable.

Technical Analysis

Trend: Bearish overall (SMA_200 > SMA_20 > SMA_5), indicating price is still below key longer-term averages.
Momentum: MACD histogram is positive and expanding (0.00335), suggesting early stabilization/turn attempt, but not a confirmed uptrend.
RSI (6): 51.55 (neutral) — no strong overbought/oversold edge.
Key levels: Pivot 2.19; Support S1 2.06 / S2 1.98; Resistance R1 2.32 / R2 2.40. With pre-market ~2.22, the stock is closer to resistance than deep support, reducing immediate upside room.
Stat/pattern outlook: 70% chance of ~-1.52% next day; +0.69% next week; +10.51% next month — near-term choppy-to-down, better skew over a month.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Positive Catalysts

- Insiders are buying aggressively (buying amount up ~221.99% over the last month), often a supportive signal around depressed prices.
- MACD turning positive/expanding suggests selling pressure may be easing.
- Gross margin improved YoY (71.77%, +1.84%), indicating solid unit economics despite slower top-line growth.
- Analyst still maintains a Buy rating with a target well above the current price (even after a cut).

Neutral/Negative Catalysts

- Financial performance is weakening YoY (revenue, EPS, and net income all down in the latest reported quarter).
- Moving averages remain bearishly stacked, implying the primary trend is still down.
- Truist cut the price target ($6 → $5), signaling tempered expectations.
- No news/catalyst in the last week to drive an immediate re-rating.
- No recent congress trading data; no confirmed politician/influencer activity supporting a near-term catalyst.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 47.956M, -6.67% YoY (top-line contraction).
Net income: 8.1888M, -23.49% YoY (profit decline faster than revenue).
EPS: 0.22, -33.33% YoY (meaningful earnings compression).
Gross margin: 71.77%, +1.84% YoY (margin resilience is a bright spot, but it hasn’t prevented EPS decline).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2026-01-07 (Truist): Price target lowered to $5 from $6, rating kept at Buy.
Wall Street pro view (pros): Maintained Buy suggests continued conviction; target implies substantial upside vs. ~2.22.
Wall Street con view (cons): Target cut indicates reduced near-to-midterm optimism; combined with declining YoY earnings, the market may keep discounting the stock until growth re-accelerates.

4 Analyst Rating

Wall Street analysts forecast BTMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTMD is 4 USD with a low forecast of 3 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.230

Low

Averages

High

Current: 2.230

Low

Averages

High

Truist

Buy

downgrade

$6 -> $5

AI Analysis

2026-01-07

Reason

Truist

Price Target

$6 -> $5

AI Analysis

2026-01-07

downgrade

Buy

Reason

Truist lowered the firm's price target on Biote to $5 from $6 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into 2026, the analyst tells investors in a research note.

B. Riley

Jeff Van Sinderen

Neutral

downgrade

$4 -> $3

2025-11-06

Reason

B. Riley

Jeff Van Sinderen

Price Target

$4 -> $3

2025-11-06

downgrade

Neutral

Reason

B. Riley analyst Jeff Van Sinderen lowered the firm's price target on Biote to $3 from $4 and keeps a Neutral rating on the shares. The firm reduced estimates post the Q3 report.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BTMD

Unlock Now

BTMD Should I Buy

BTMD Should I Buy

Should You Buy Biote Corp (BTMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch